Cancer » lymphoma - Lectures

Closing Remarks

New drugs

Milestones in Hodgkin Lymphoma

Radiotherapy

Milestones in Hodgkin Lymphoma

Prognostic indices and PET

Milestones in Hodgkin Lymphoma

Pathology

Milestones in Hodgkin Lymphoma

PET adapted sequential salvage therapy with brentuximab vedotin and augmented ICE for transplant eligible patients with relapsed and refractory Hodgkin Lymphoma

Relapsed

Debate: Is there still a role for allogeneic TX in Hodgkin Lymphoma? Contra

Relapsed

What’s new in relapsed Hodgkin Lymphoma?

Relapsed

Standard ABVD vs. escalated BEACOPP in stage III – IV low risk Hodgkin Lymphoma (IPS 0-2): the Lymphoma Study Association (LYSA) H34 trial

Advanced stages

Can we improve ABVD?

Advanced stages

Risk-adapted therapy in advanced stage Hodgkin Lymphoma: An Update

Advanced stages

A Dutch nationwide survivorship care programme for Hodgkin Lymphoma survivors

Survivorship

Changes in breast cancer risk as long-term Hodgkin Lymphoma survivors reach menopausal age

Survivorship

Breast Cancer and other Neoplasms

Survivorship

Cardiac toxicity

Survivorship

Overview of the challenges encountered by the Pediatric International Harmonization Criteria Workshop

Beyond the International Harmonization Criteria

Nuclear medicine aspects of the International Harmonization Criteria, as they apply to pediatrics

Beyond the International Harmonization Criteria

Practical experience in the application of the International Harmonization Criteria – as viewed by a medical oncologist

Beyond the International Harmonization Criteria

Very early response as measured by (18F)-fluorodeoxyglucose-positron emission tomography (FDG-PET) after one cycle of chemotherapy in newly diagnosed pediatric / adolescent low risk Hodgkin Lymphoma (HL)

PET and prediction

PET review in GHSG trials

PET and prediction